{"id":71379,"date":"2026-07-30T18:44:43","date_gmt":"2026-07-30T10:44:43","guid":{"rendered":"https:\/\/flcube.com\/?p=71379"},"modified":"2026-07-30T18:44:44","modified_gmt":"2026-07-30T10:44:44","slug":"xgene-pharmaceutical-secures-35m-series-d-funding-to-advance-non-opioid-pain-therapy-xg005-into-phase-iii-trials-in-the-us","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71379","title":{"rendered":"Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US"},"content":{"rendered":"\n

Xgene Pharmaceutical Inc.<\/strong> announced the successful completion of a RMB 250 million ($35 million)<\/strong> Series D financing round to advance its lead non-opioid analgesic candidate XG005<\/strong> into Phase III clinical trials for acute pain in the United States<\/strong>. The round was co-led by YF Capital and HighTone Investment<\/strong>, with participation from Jiaxing Yuanfan, Real Capital Global<\/strong>, and one additional undisclosed institutional investor. Keywise Capital<\/strong> served as exclusive financial advisor for the transaction.<\/p>\n\n\n\n

Financing Details<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Amount Raised<\/strong><\/td>RMB 250 million (~$35 million USD)<\/td><\/tr>
Round<\/strong><\/td>Series D<\/td><\/tr>
Lead Investors<\/strong><\/td>YF Capital, HighTone Investment<\/td><\/tr>
Participating Investors<\/strong><\/td>Jiaxing Yuanfan, Real Capital Global, plus one additional institution<\/td><\/tr>
Financial Advisor<\/strong><\/td>Keywise Capital<\/td><\/tr>
Primary Use of Proceeds<\/strong><\/td>Phase III acute pain clinical trial for XG005 in the US; global pipeline advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Unmet Need<\/h2>\n\n\n\n

The global opioid crisis continues to pose significant public health challenges, with over 80,000 opioid-related overdose deaths annually in the US alone<\/strong>. Despite decades of use, opioids remain associated with substantial risks including dependence, abuse potential, respiratory depression, and constipation<\/strong>. This has created a critical unmet need for non-opioid analgesics<\/strong> that can deliver comparable efficacy with improved safety profiles<\/strong>.<\/p>\n\n\n\n

The global pain management market<\/strong> is projected to reach $85 billion by 2028<\/strong>, with non-opioid segments experiencing accelerated growth driven by regulatory pressure, payer restrictions, and physician preference shifts away from controlled substances.<\/p>\n\n\n\n

Company Profile & Pipeline Strategy<\/h2>\n\n\n\n